Ironwood Stock Price, News & Analysis

Ironwood Pharmaceuticals (Nasdaq: IRWD) presented new findings at the 2022 Digestive Disease Week that suggest IW-3300 could manage abdominal pain in patients with disorders of gut-brain interaction. Current Phase I trials aim to explore this compound's potential for visceral pain conditions, including interstitial cystitis and endometriosis. The company also shared insights on the efficacy of linaclotide in treating IBS-C and functional constipation in pediatric patients, aiming to address the unmet needs in gastrointestinal diseases.

Ironwood Pharmaceuticals (Nasdaq: IRWD) will showcase eight studies, including two oral presentations, at the Digestive Disease Week 2022 conference in San Diego from May 21 to May 24. One key study focuses on IW-3300's effect on chronic pelvic pain, while another analyzes linaclotide's impact on abdominal symptoms in IBS-C patients. CEO Tom McCourt will receive the ASGE President’s Award for his contributions to gastrointestinal endoscopy, highlighting Ironwood's ongoing commitment to GI health advancements.

Ironwood Pharmaceuticals (Nasdaq: IRWD) reported Q1 2022 results, highlighting an 11% year-over-year growth in LINZESS® (linaclotide) prescription demand. The U.S. net sales of LINZESS reached $232 million, marking an 8% increase year-over-year. Total revenue for the quarter was $98 million, with collaboration revenue from LINZESS at $94 million. The company achieved a GAAP net income of $39 million and ended the quarter with $593 million in cash. Ironwood remains focused on pipeline development and ongoing clinical trials for new GI treatments.

Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2022 investor update conference call on May 5, 2022, at 8:30 a.m. Eastern Time. Participants can join via phone or access a webcast from Ironwood's website. A replay will be available from 11:30 a.m. ET on the same day until May 19, 2022. Ironwood is known for its development of LINZESS®, a leading treatment for gastrointestinal diseases, aiming to improve care standards for patients with IBS-C and CIC.

Ironwood Pharmaceuticals (Nasdaq: IRWD), a leading gastrointestinal healthcare company, announced management presentations at two key investor conferences. The events include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. Live webcasts of these presentations will be available on Ironwood's website, with replays accessible for 14 days after the conferences. Ironwood is dedicated to advancing treatment for GI diseases, notably with its leading product LINZESS®.

Ironwood Pharmaceuticals (Nasdaq: IRWD) reported a strong financial performance for 2021, with total revenues reaching $414 million, driven largely by $400 million from U.S. LINZESS collaboration revenue. The company reported a GAAP net income of $528 million, boosted by a non-recurring tax benefit. Ironwood also made strategic advancements in its pipeline, initiating clinical studies for IW-3300 and CNP-104, targeting unmet medical needs in visceral pain and primary biliary cholangitis (PBC). The company ended 2021 with $620 million in cash and equivalents, positioning itself favorably for growth in 2022.

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an investor update conference call for its fourth quarter and full year 2021, scheduled for February 17, 2022, at 8:30 a.m. ET. Participants can dial in at (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230. The call will be available for replay after 11:30 a.m. ET on the same day until March 3, 2022. Ironwood is focused on advancing treatments for gastrointestinal diseases, led by its product LINZESS®.

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced strong financial guidance, projecting LINZESS to exceed $1 billion in U.S. net sales for 2021, achieving blockbuster status. The company authorized a share repurchase program worth $150 million. For 2022, Ironwood expects low single-digit net sales growth for LINZESS, total revenues of $420-$430 million, and adjusted EBITDA exceeding $250 million. The company will present these insights at the J.P. Morgan Healthcare Conference on January 12, 2022.

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced that CEO Tom McCourt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The presentation will be held virtually, and investors can access the live audio webcast via the company’s website. A replay will be available for 14 days post-conference. Ironwood is focused on advancing treatments for gastrointestinal diseases, including its flagship product LINZESS® for IBS-C and CIC.